Taysha Gene Therapies Inc —— 资产负债表 (NASDAQ:TSHA) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 258.88 M213.96 M126.28 M172.73 M160.36 M343.32 M 负债总额 7.58 M118.57 M125.33 M97.79 M88.84 M96.38 M 权益总额 251.3 M95.38 M949 K74.94 M71.53 M246.94 M 负债及股东权益总额 258.88 M213.96 M126.28 M172.73 M160.36 M343.32 M 总债务 —37.19 M38.29 M40.86 M44.33 M50.48 M 净债务 —-111.91 M-49.59 M-103.08 M-94.7 M-269.28 M

新闻

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript

Taysha Gene面临财报考验,Rett综合征试验取得进展

Taysha Gene faces earnings test as Rett trial advances

从实验室到股市飙升：富国银行选出2026年SMID-Cap生物科技领军股

Stifel 重申 Neurogene 股票买入评级，认为其具有可行安全边际

Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin

Taysha为Rett综合征基因疗法关键试验给首位患者用药

Taysha doses first patient in pivotal Rett syndrome gene therapy trial

泰莎基因治疗股价创52周新高至5.98美元

Taysha Gene Therapies stock hits 52-week high at $5.98

2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标

生物科技股：杰富瑞列出2026年六大首选股票